Jain A, Lim C, Gan EM, Ng DZ, Ng QS, Ang MK, Takano A, Chan KS, Tan WM, Kanesvaran R, Toh CK, Loo CM, Hsu AA, Devanand A, Lim CH, Koong HN, Koh TP, Fong KW, Yap SP, Kim SW, Chowbay B, Oon L, Lim KH, Lim WT, Tan EH, Tan DS (2015) Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors . PLoS ONE 10(5) : e0123587 PMID:25955322
Ong WS, Toh CK, Tan DSW, Chau NM, Ng QS, Ang MK, Tan EH, Lim WT. Lung cancer outcomes in an era of more options: Survival analysis from an Asian cancer center. WLCC, Sydney 2013
Tan DSW, Ong WS, Ahmad A, Tai DWM, Ang MK, Ng QS, Kanesevaran R, Choo SP, Ng MCH, Tan EH, Lim WT. Outcomes of NSCLC patients on Phase I Trials: The importance of molecular and patient selection. WLCC, Sydney 2013.
Tan WC, Jain A, Barbier S, Ng QS, Kanesvaran R, Ang MK, Takano A, Lim KH, Tan WM, Toh CK, Chakraborty B, Lim WT, Tan EH, Tan DSW. Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI). J Clin Oncol 32, 2014 (suppl; abstr e19101)
Zeng WL, Lim WT, Tan EH, Toh CK, Tan DSW. Differences in clinical characteristics and overall survival in never-smokers with lung squamous cell carcinoma. J Clin Oncol 32, 2014 (suppl; abstr e12527).
Tan JZE, Ong WS, Tan DSW, Takano A, Lim TKH, Chan KS, Oon L, Lim AST, Jain A, Toh CK, Ang MK, Ng QS, Kanesvaran R, Devanand A, Lim CH, Koh TPT, Lim WT, Tan EH. Reflex testing of EGFR and ALK in non-squamous non-small cell lung cancer. World Conference in Lung Cancer Sept 2015; Denver, Colorado, USA.
Tan DSW, Nahar R, Takano A, Khng AJ, Zhang T, Koh T, Gogna A, Lim KH, Liu X, Teo ASM, Chan CX, , Lee YY, Iyer NG, Chen LH, Ang MK, Ng QS, Toh CK, Kanesvaran R, Jain A, Devanand A, Krishnan VG, Ng PC, Tan BS, Lim CH, Chowbay B, Lim WT, Tam WL, Lim B, Tan EH, Zhai WW, Hillmer AM. Multiregion whole exome and transcriptome sequencing defines the genomic spectrum of EGFR+ NSCLC and reveals novel mechanisms of TKI resistance. World Conference in Lung Cancer Sept 2015; Denver, Colorado, USA.
Ang J, Tan SH, Tan DSW, Kim SW, Fong KW, Ang MK, Lim WT, Tan EH, Toh CK, Kanesvaran R, Ng QS. Chemo-radiotherapy in stage III non-small cell lung carcinoma: does the choice of chemotherapy matter? European Cancer Congress 2015 Vienna, Austria.
Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, Tan DS (2016) Novel therapeutic targets on the horizon for lung cancer . Lancet Oncol 17(8) : e347-62 PMID:27511159
Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo ASM, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JWJ, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY Koh LP, Chowbay B, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet IE, Ang MK, Chau NM, Ng QS, Tan DSW, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18: 521-8.
